Backed by 40-plus years of experience, the new Grandview Max stakes it claim as this spring's open-toed outdoor overlord.

Teva's stock is a speculative buy with potential upside if biosimilars succeed, but risks remain high due to debt and ...

The company is leaning on its subcutaneous technology to deliver long-acting options that could prevent patients from cycling through drugs.

We recently compiled a list of the 12 Best Low Price Pharma Stocks To Invest In Right Now. In this article, we are going to ...

NORTHAMPTON, MA / ACCESS Newswire / February 27, 2025 / In high-income countries, more than 80% of children diagnosed with ...

The application leverages existing clinical data for Uzedy along with prior FDA findings on the safety of Udezy in patients ...

Teva Pharmaceutical Industries Ltd.'s bid to dismiss antitrust claims should be denied in a case where Mylan Pharmaceuticals Inc. alleges the company unlawfully delayed a generic version of a multiple ...

Teva and Sanofi's duvakitug showed promising results in a Phase 2b study for ulcerative colitis and Crohn's disease, with ...

Teva Pharmaceuticals (TEVA) and Medincell (MEDCL) announced that the supplemental New Drug Application sNDA for UZEDY extended-release ...

New York, New York-- (Newsfile Corp. - March 1, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Semtech Corp. (NASDAQ: SMTC) and certain ...

Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be ...